<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-41655" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Aprepitant</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ritchie</surname>
            <given-names>Michael K.</given-names>
          </name>
          <aff>West Virginia University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kohli</surname>
            <given-names>Arpan</given-names>
          </name>
          <aff>West Virginia University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Ritchie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Arpan Kohli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-41655.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Aprepitant was initially developed to prevent chemotherapy-induced nausea and vomiting (CINV). However, its applications have since broadened to include postoperative nausea and vomiting (PONV). Aprepitant&#x000a0;belongs to the neurokinin-1 antagonist class of medications and has received approval from the Food and Drug Administration (FDA) for both indications. This activity outlines and reviews the indications, actions, and contraindications of aprepitant as a valuable drug in preventing CINV and PONV. This activity also highlights the mechanism of action, adverse event profile, monitoring, and relevant interactions pertinent for healthcare team members involved in the care of patients undergoing highly emetogenic chemotherapy or general anesthesia.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate patient candidates for aprepitant therapy based on the risk factors for chemotherapy-induced nausea and vomiting and postoperative nausea and vomiting.</p></list-item><list-item><p>Assess and monitor patients for potential adverse events associated with aprepitant therapy and promptly manage any complications.</p></list-item><list-item><p>Select appropriate dosing regimens of aprepitant based on the specific chemotherapy or anesthesia regimen.</p></list-item><list-item><p>Collaborate with healthcare professionals to ensure proper dosing, monitor drug interactions, and address concerns related to aprepitant for optimal patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=41655&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=41655">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-41655.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Aprepitant and fosaprepitant are drugs used to prevent nausea and vomiting in cancer patients. Aprepitant can be taken orally or intravenously (IV), whereas fosaprepitant is an IV prodrug. Aprepitant was initially developed to prevent chemotherapy-induced nausea and vomiting (CINV). However, its applications have since broadened to include postoperative nausea and vomiting (PONV).</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Aprepitant&#x000a0;belongs to the neurokinin-1 antagonist class of medications and has received approval from the Food and Drug Administration (FDA) for both indications.<xref ref-type="bibr" rid="article-41655.r1">[1]</xref><xref ref-type="bibr" rid="article-41655.r2">[2]</xref><xref ref-type="bibr" rid="article-41655.r3">[3]</xref>&#x000a0;Research suggests that aprepitant may exhibit antiproliferative, antiangiogenic, and antimetastatic effects.<xref ref-type="bibr" rid="article-41655.r4">[4]</xref><xref ref-type="bibr" rid="article-41655.r5">[5]</xref> The interaction system between substance P and the neurokinin-1 receptor (NK-1R) is recognized for its pivotal role in cancer pathophysiology. As an NK-1R antagonist, aprepitant&#x000a0;shows potential in enhancing antitumor activity. Aprepitant's potential to complement major chemotherapeutic agents makes it a promising&#x000a0;broad-spectrum antitumor drug for&#x000a0;various cancers. This approach can revolutionize cancer treatment, providing heightened efficacy and improved patient outcomes if validated.<xref ref-type="bibr" rid="article-41655.r6">[6]</xref>&#x000a0;</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Studies indicate that aprepitant may have potential applications in managing chronic refractory pruritus.&#x000a0;According to<bold>&#x000a0;</bold>the National Comprehensive Cancer Network (NCCN), aprepitant may be considered for treating refractory pruritus caused by immunotherapy-related toxicities.<xref ref-type="bibr" rid="article-41655.r7">[7]</xref><bold>&#x000a0;</bold>However, substantiating the efficacy and safety of aprepitant for the indications mentioned above requires thorough investigation through randomized controlled trials (RCTs).<xref ref-type="bibr" rid="article-41655.r8">[8]</xref><xref ref-type="bibr" rid="article-41655.r9">[9]</xref></p>
      </sec>
      <sec id="article-41655.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Aprepitant is a highly selective antagonist of the G-protein&#x02013;coupled NK-1R.<xref ref-type="bibr" rid="article-41655.r10">[10]</xref><xref ref-type="bibr" rid="article-41655.r11">[11]</xref><xref ref-type="bibr" rid="article-41655.r12">[12]</xref>&#x000a0;NK-1 receptors are present in the central and peripheral nervous systems, with substance P, a nociceptive neurotransmitter, as their primary ligand.&#x000a0;The brainstem regions believed to have crucial roles in the vomiting reflex include the central pattern generator, the nucleus tractus solitarius, and the area postrema.<xref ref-type="bibr" rid="article-41655.r13">[13]</xref><xref ref-type="bibr" rid="article-41655.r14">[14]</xref><xref ref-type="bibr" rid="article-41655.r15">[15]</xref></p>
        <p>Central NK-1Rs are distributed across these regions, enabling extensive binding of aprepitant in these vital areas. By functioning as a competitive antagonist in these regions, aprepitant is believed to significantly attenuate the likelihood of initiating the complex vomiting reflex.<xref ref-type="bibr" rid="article-41655.r16">[16]</xref>&#x000a0;Peripherally, NK-1Rs exist throughout the gastrointestinal tract. The binding of the aprepitant to NK-1Rs may attenuate vagal afferent signals, thereby contributing to the antiemetic effect. The proposed mechanism for the antipruritic effect involves the antagonism of substance P&#x02014;an endogenous ligand of the NK-1R.<xref ref-type="bibr" rid="article-41655.r8">[8]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Aprepitant exhibits nonlinear pharmacokinetics, and its bioavailability decreases with increasing dose. The mean oral bioavailability of aprepitant is 67% for 80 mg and 59% for 125 mg capsules. Peak plasma concentration is attained in 4 hours.<xref ref-type="bibr" rid="article-41655.r17">[17]</xref></p>
        <p><bold>Distribution:</bold>&#x000a0;Aprepitant has high plasma protein binding of approximately 95% and a high&#x000a0;volume of distribution at a steady state (Vss) of 70 L.</p>
        <p><bold>Metabolism:</bold>&#x000a0;Aprepitant undergoes hepatic metabolism primarily by P450 CYP3A4 and CYP2C9, with minor contributions from CYP1A2 and CYP2C19. Major metabolites include N and O dealkylation products, which are pharmacologically inactive. Notably, aprepitant acts as a dose-dependent inhibitor and inducer of CYP3A4.<xref ref-type="bibr" rid="article-41655.r18">[18]</xref></p>
        <p><bold>Elimination:</bold> Metabolites of aprepitant are excreted with approximately 50% in urine and 50% in feces. Minimal renal excretion of the parent drug is observed.<xref ref-type="bibr" rid="article-41655.r19">[19]</xref></p>
      </sec>
      <sec id="article-41655.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Aprepitant is available as a capsule for PO administration, with strengths of 40 mg, 80 mg, and 125 mg. In addition, it is available as a prodrug preparation named fosaprepitant for&#x000a0;IV administration. Fosaprepitant is supplied in powder form for reconstitution, with a strength of 150 mg per vial. A standard recommendation for highly emetogenic&#x000a0;CINV prevention involves administering a 125-mg aprepitant capsule PO 1 hour before administering chemotherapy on day 1. This is often combined with a 5-HT3 antagonist and dexamethasone.</p>
        <p>
<bold>Adult&#x000a0;Dosage</bold>
</p>
        <p>The 80-mg capsule is administered 1 hour before chemotherapy on days 2 and 3, often combined with a 5-HT3 antagonist and dexamethasone. The IV preparation, fosaprepitant, is administered as a single dose of 150 mg 30 minutes before chemotherapy, and repeat dosing is not required.<xref ref-type="bibr" rid="article-41655.r18">[18]</xref><xref ref-type="bibr" rid="article-41655.r20">[20]</xref>&#x000a0;Multiple dosing regimens are available depending on the prescribed chemotherapy regimen and institutional practices. In addition, it is advisable to consult with the treating oncologist and pharmacist and refer to current reference literature for the most up-to-date information.</p>
        <p><bold>Chemotherapy-induced nausea and vomiting:</bold> Chemotherapy agents are categorized into 5 emetogenic levels, each indicating the anticipated frequency of emesis in the absence of prophylactic antiemetics.</p>
        <list list-type="bullet">
          <list-item>
            <p>High: &#x0003e;90% risk of emesis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Moderate: &#x0003e;30% and &#x02264;90% risk of emesis</p>
          </list-item>
          <list-item>
            <p>Low: &#x02265;10% and &#x0003c;30% risk of emesis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Minimal: &#x0003c;10% risk of emesis</p>
          </list-item>
        </list>
        <p>The American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), and&#x000a0;NCCN have developed antiemetic therapy-based guidelines based on the risk of emesis.&#x000a0;An NK-1R antagonist is recommended in combination with a 5-HT3 receptor antagonist (such as&#x000a0;ondansetron) and a glucocorticoid (often dexamethasone) for highly emetogenic chemotherapy (HECT) and moderately emetogenic chemotherapy (MECT).</p>
        <list list-type="bullet">
          <list-item>
            <p>MECT-aprepitant (1-day regimen):
<list list-type="bullet"><list-item><p>Aprepitant: 130 mg administered via IV route</p></list-item><list-item><p>Dexamethasone: 12 mg orally (administered 30 minutes before chemotherapy treatment)</p></list-item><list-item><p>5-HT3 antagonist</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>MECT-aprepitant (3-day regimen): Day 1
<list list-type="bullet"><list-item><p>Aprepitant: 100 mg administered via&#x000a0;IV route</p></list-item><list-item><p>Dexamethasone: 12 mg orally (administered 30 minutes before chemotherapy treatment)</p></list-item><list-item><p>5-HT3 antagonist: Healthcare providers should follow the selected 5-HT3 antagonist prescribing information for the recommended dosage</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>MECT-aprepitant (3-day regimen): Day 2
<list list-type="bullet"><list-item><p>Aprepitant: 80 mg administered&#x000a0;orally</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>MECT-aprepitant (3-day regimen): Day 3
<list list-type="bullet"><list-item><p>Aprepitant: 80 mg administered&#x000a0;orally</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>HECT-aprepitant (single-dose regimen): Day 1
<list list-type="bullet"><list-item><p>Aprepitant: 130 mg administered via&#x000a0;IV route</p></list-item><list-item><p>Dexamethasone: 12 mg orally (administered 30 minutes before chemotherapy treatment)</p></list-item><list-item><p>5-HT3 antagonist</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>HECT-aprepitant (single-dose regimen): Day 2
<list list-type="bullet"><list-item><p>Dexamethasone: 8 mg administered&#x000a0;orally once daily in the morning</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>HECT-aprepitant (single-dose regimen): Day 3&#x000a0;
<list list-type="bullet"><list-item><p>Dexamethasone: 8 mg administered&#x000a0;orally twice daily</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>HECT-aprepitant (single-dose regimen): Day 4&#x000a0;
<list list-type="bullet"><list-item><p>Dexamethasone: 8 mg administered&#x000a0;orally twice daily</p></list-item></list>
</p>
          </list-item>
        </list>
        <p><bold>PONV and post-discharge nausea and vomiting (PDNV):</bold> The 40-mg aprepitant capsule is administered PO within 3 hours of induction to prevent anesthesia-induced PONV. Due to its increased cost compared with other antiemetics used in anesthesia practice, its utilization should be reserved for patients at a high risk of nausea and vomiting or for those in whom vomiting could compromise surgical repair. The Apfel score is a validated and frequently used scoring system to predict&#x000a0;PONV risk.&#x000a0;Antiemetic regimens that include aprepitant can be recommended according to the calculated risk. Although fosaprepitant has not received an indication for PONV, ongoing exploration for its future use in NPO (nothing by mouth) patients is under exploration. It is expected to have similar efficacy to an equipotent dose of aprepitant.<xref ref-type="bibr" rid="article-41655.r21">[21]</xref><xref ref-type="bibr" rid="article-41655.r22">[22]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> No dosage adjustment is necessary for aprepitant in cases of mild-to-moderate hepatic impairment. Caution is advised in instances of severe hepatic impairment (Child-Pugh score &#x0003e;9).</p>
        <p><bold>Renal impairment:&#x000a0;</bold>No dosage adjustment of aprepitant is necessary for aprepitant in cases of renal impairment or end-stage renal disease undergoing hemodialysis.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>The review indicates that aprepitant can be safely used during the first trimester of pregnancy. Aprepitant is classified as a former FDA pregnancy category B drug.<xref ref-type="bibr" rid="article-41655.r23">[23]</xref>&#x000a0;In addition, clinicians recommend a comprehensive evaluation of the risks and benefits to be carried out, and healthcare providers should involve patients in decision-making through shared decision-making.<xref ref-type="bibr" rid="article-41655.r24">[24]</xref></p>
        <p><bold>Breastfeeding considerations: </bold>Limited clinical data are available regarding the use of aprepitant during breastfeeding. Clinicians should weigh the developmental and health benefits of breastfeeding, the clinical necessity for aprepitant in the mother, and potential adverse drug reactions in the breastfed infant.</p>
        <p><bold>Pediatric patients: </bold>The IV formulation of aprepitant is FDA-approved for use in pediatric patients.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>CINV: Oral capsules may be administered similarly to adult patients when the pediatric patient is either 12 or older or 12 or younger but has a body weight of more than 30 kg.<xref ref-type="bibr" rid="article-41655.r18">[18]</xref>&#x000a0;Aprepitant is available in oral suspension prepared by mixing the contents of 1 pouch of powder with 4.6 mL of water. This resultant suspension provides a strength of 25 mg/mL for oral administration, suitable for pediatric patients or adults unable to swallow capsules. The oral suspension is the preferred dosage form for pediatric patients aged 6 months or older and up to age 12 or with a body weight of less than 30 kg. A standard regimen for&#x000a0;HECT is 3 mg/kg PO 1 hour before chemotherapy on day 1 and 2 mg/kg PO 1 hour before chemotherapy on day 2.<xref ref-type="bibr" rid="article-41655.r25">[25]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>Similar to adults, aprepitant is frequently combined with a weight-based dose of ondansetron and dexamethasone on both days. In cases where the patient cannot tolerate oral administration and has intravenous access, fosaprepitant may be substituted for the oral suspension. Fosaprepitant dosing is age-stratified and varies within the age group, depending on whether it is used as a monotherapy or in combination with dexamethasone and a 5-HT3 antagonist.&#x000a0;Notably, multiple dosing regimens exist based on the prescribed chemotherapy regimen and institutional practices, just as in adults. Therefore, it is advisable to consult with the treating oncologist and pharmacist and review current reference literature for guidance.</p>
        <list list-type="bullet">
          <list-item>
            <p>PONV and PDNV: Aprepitant and fosaprepitant have not received FDA approval for preventing anesthesia-induced PONV in the pediatric population. However, existing literature demonstrates their efficacy and safety in this context.<xref ref-type="bibr" rid="article-41655.r26">[26]</xref></p>
          </list-item>
        </list>
        <p><bold>Older patients:</bold> Dosage adjustments should be considered in the presence of renal or hepatic impairment and polypharmacy situations.</p>
      </sec>
      <sec id="article-41655.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Aprepitant and fosaprepitant are generally very well tolerated with minimal adverse effects. Their tolerability is comparable to other antiemetics, such as single doses of ondansetron, characterized by a low adverse event profile.<xref ref-type="bibr" rid="article-41655.r18">[18]</xref> Common, less common, and rare adverse effects, as mentioned below, exhibit a lower incidence when aprepitant is dosed at 40 mg orally for PONV prophylaxis compared to higher doses and multiple administration CINV prophylaxis regimens.<xref ref-type="bibr" rid="article-41655.r27">[27]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>A systematic review of 17 RCTs indicated that patients receiving aprepitant reported adverse drug reactions, including hiccups, fatigue, asthenia, and severe infections.<xref ref-type="bibr" rid="article-41655.r28">[28]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Common adverse effects include headache, fatigue, anorexia, constipation, diarrhea, nausea, and hiccups, with an incidence greater than 10%.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Less common adverse effects include dizziness, insomnia, bradycardia, hypotension, pharyngolaryngeal pain, mucosal inflammation, stomatitis, dyspepsia, anemia, neutropenia, hot flash, pruritus, dehydration, and fever, with an incidence of 1% to 10%.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rare adverse effects include candidiasis, staphylococcal infection, febrile neutropenia, weight gain, polydipsia, disorientation, euphoria, vivid dreams, cognitive disorder, lethargy, somnolence, conjunctivitis, cough, acid reflux, epigastric discomfort, malaise, and chills, with an incidence less than 1%.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients taking oral contraceptive medications should use a backup means of contraception or abstain from sexual activity to mitigate the risk of an unplanned pregnancy. A pregnancy test is advisable if the patient misses a menstrual cycle.<xref ref-type="bibr" rid="article-41655.r29">[29]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Aprepitant functions as a dose-dependent inhibitor and inducer of the cytochrome P450 CYP3A4 enzyme family. In addition, aprepitant also induces CYP2C9. Medications or substances metabolized through this pathway may be affected, leading to clinically appreciable effects. Commonly cited interactions include benzodiazepines, warfarin, ketoconazole, and dexamethasone. Furthermore, it&#x000a0;is recommended to reduce the dose of dexamethasone when coadministered with aprepitant or fosaprepitant.<xref ref-type="bibr" rid="article-41655.r30">[30]</xref><xref ref-type="bibr" rid="article-41655.r31">[31]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>CYP3A4 metabolizes oxycodone to its active metabolite, oxymorphone, and may result in increased exposure to oxymorphone when administered with aprepitant. Therefore, close monitoring of patients is crucial during concurrent therapy. Aprepitant's induction of CYP3A4 can affect hormonal contraceptives, potentially resulting in oral contraceptive failure. Patients should be advised to use an alternative&#x000a0;method of contraception. Quetiapine, a CYP3A4 substrate, exhibits increased plasma levels when coadministered with aprepitant.<xref ref-type="bibr" rid="article-41655.r32">[32]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>IV compatibility: IV aprepitant is compatible with 5% dextrose injection and 0.9% sodium chloride injection.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>IV incompatibility:&#x000a0;IV aprepitant is incompatible with solutions containing divalent cations, such as magnesium and calcium, including Ringer lactate and Hartmann solutions.<xref ref-type="bibr" rid="article-41655.r33">[33]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-41655.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Few contraindications exist to the use of aprepitant or fosaprepitant.<xref ref-type="bibr" rid="article-41655.r30">[30]</xref><xref ref-type="bibr" rid="article-41655.r31">[31]</xref></p>
        <p>Commonly cited contraindications include prior hypersensitivity reactions and the coadministration of pimozide or cisapride. Pimozide, a CYP3A4 substrate, may have increased plasma levels when CYP3A4 is inhibited by aprepitant, thereby elevating the risk of QT prolongation.<xref ref-type="bibr" rid="article-41655.r8">[8]</xref></p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>Aprepitant is a weak CYP3A4 inhibitor. Relative contraindications include medications metabolized via CYP3A4, such as ifosfamide and vincristine, or those with narrow therapeutic indexes. Decreased metabolism of these medications may lead to increased toxicity.<xref ref-type="bibr" rid="article-41655.r30">[30]</xref></p>
      </sec>
      <sec id="article-41655.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>There is no need for routine monitoring and, hence, no recommendations for it.</p>
        <p>A pregnancy test is necessary if the patient misses a menstrual cycle.<xref ref-type="bibr" rid="article-41655.r29">[29]</xref>&#x000a0;Combining aprepitant (a weak CYP2C9 inducer) with warfarin (a CYP2C9 substrate) may lead to a reduced international normalized ratio (INR). Patients taking warfarin should undergo a prothrombin time (PT/INR) check 1 week after aprepitant administration with the chemotherapy cycle.<xref ref-type="bibr" rid="article-41655.r30">[30]</xref><xref ref-type="bibr" rid="article-41655.r21">[21]</xref> The quality of life and clinical response to aprepitant should be monitored using a modified Functional Living Index-Emesis (FLIE) or FLIE score.<xref ref-type="bibr" rid="article-41655.r34">[34]</xref><xref ref-type="bibr" rid="article-41655.r35">[35]</xref><xref ref-type="bibr" rid="article-41655.r36">[36]</xref></p>
      </sec>
      <sec id="article-41655.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Aprepitant has a very high therapeutic index, and case reports of toxicity due to overdose are sparse or nonexistent. No specific antidote exists for aprepitant toxicity.<xref ref-type="bibr" rid="article-41655.r37">[37]</xref> Although serum aminotransferase elevations occur in 6% of treated patients, clinically apparent liver injury is rare.<xref ref-type="bibr" rid="article-41655.r38">[38]</xref>&#x000a0;A case report of ifosfamide-induced encephalopathy exists that is associated with&#x000a0;aprepitant. The encephalopathy was reversed with supportive treatment and discontinuation of aprepitant.<xref ref-type="bibr" rid="article-41655.r39">[39]</xref>&#x000a0;</p>
        <p>The retrospective case series investigated the prolonged daily use of aprepitant for intractable nausea and vomiting in children in palliative care settings. In comparison with the standard regimen, the mean number of days of aprepitant&#x000a0;treatment&#x000a0;was 36.5 days, ranging from 6&#x000a0;to 84 days. No adverse events were observed even after prolonged administration of the drug, thereby establishing the safety profile of aprepitant.<xref ref-type="bibr" rid="article-41655.r40">[40]</xref> In the event of an overdose, it is recommended to implement supportive care, consult&#x000a0;a medical toxicologist, or contact a poison control center.<xref ref-type="bibr" rid="article-41655.r41">[41]</xref></p>
      </sec>
      <sec id="article-41655.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>CINV and PONV result in decreased patient satisfaction, increased patient stress, and potentially increased admission rates or delayed discharge from healthcare facilities.<xref ref-type="bibr" rid="article-41655.r42">[42]</xref> Emerging as well-tolerated and highly effective novel therapies with minimal adverse effects are evolving. Aprepitant and its IV prodrug, fosaprepitant, belong to a new class of antiemetics known as neurokinin-1 inhibitors. These highly selective medications bind to multiple areas in the brainstem responsible for initiating and coordinating the vomiting reflex.<xref ref-type="bibr" rid="article-41655.r13">[13]</xref><xref ref-type="bibr" rid="article-41655.r15">[15]</xref>&#x000a0;</p>
        <p>Aprepitant binds to NK-1Rs in multiple brainstem areas, exerting its antiemetic effect for up to 48 hours.<xref ref-type="bibr" rid="article-41655.r16">[16]</xref><xref ref-type="bibr" rid="article-41655.r20">[20]</xref> When used as monotherapy or in combination with other antiemetics, aprepitant-fosaprepitant can offer highly effective prophylaxis for CINV and PONV. In cases of CINV refractory to all medical treatments, including aprepitant, further evaluation and workup are necessary to assess for electrolyte abnormalities, intestinal obstruction, and central nervous system metastases.<xref ref-type="bibr" rid="article-41655.r43">[43]</xref></p>
        <p>In an interprofessional healthcare team comprising clinicians (MDs, DOs, NPs, and PAs), nursing staff, and pharmacists, awareness of multiple treatment options to prevent nausea and vomiting is crucial.<xref ref-type="bibr" rid="article-41655.r21">[21]</xref> Whether in the cancer center, inpatient, or operative setting, all healthcare team members must leverage their knowledge of antiemetic therapies to mitigate nausea and vomiting rates, thereby reducing adverse effects and fostering positive patient experiences.</p>
        <p>Forming interprofessional teams to develop evidence-based regimens for the prophylaxis and treatment of CINV and PONV is advisable. The incorporation of aprepitant and fosaprepitant into these regimens can result in a decreased length of hospital stay, enhanced patient satisfaction, and reduced risk of adverse events associated with the vomiting reflex, such as poor nutrition and damage to surgical repairs.<xref ref-type="bibr" rid="article-41655.r44">[44]</xref><xref ref-type="bibr" rid="article-41655.r45">[45]</xref>&#x000a0;This may require consulting with a specialized pharmacology pharmacist who can communicate with the rest of the healthcare team regarding appropriate dosing, check for interactions, provide guidance to the nursing staff on administration, and be available for additional input during post-administration monitoring. Nurses should promptly contact the ordering clinician if they observe any adverse events or changes in the patient's status.</p>
        <p>Aprepitant and fosaprepitant are relatively novel and expensive therapies compared to older antiemetics. Their use should be guided by risk stratification systems, such as the Apfel and Eberhart scores, when prescribed for&#x000a0;PONV and the updated antiemetic guidelines of the Multinational Association of Supportive Care in Cancer (MASCC)/ESMO), ASCO, and NCCN.&#x000a0;By evaluating the individual risks of patients for the development of nausea and vomiting, it is possible to optimize the cost-benefit and risk-benefit ratios.<xref ref-type="bibr" rid="article-41655.r11">[11]</xref><xref ref-type="bibr" rid="article-41655.r18">[18]</xref><xref ref-type="bibr" rid="article-41655.r27">[27]</xref><xref ref-type="bibr" rid="article-41655.r46">[46]</xref>&#x000a0;</p>
        <p>As mentioned, a board-certified oncology pharmacist can collaborate&#x000a0;with the oncology staff to ensure proper dosing and the lack of drug interactions when choosing chemotherapy-induced antiemetic therapy. The nursing staff should promptly understand the interactions and adverse event profile of these drugs and the chemotherapy to promptly inform the rest of the team if issues arise. These interprofessional strategies aim to maximize therapeutic efficacy, minimize adverse events, and optimize patient outcomes related to aprepitant therapy.</p>
      </sec>
      <sec id="article-41655.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=41655&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=41655">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/41655/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=41655">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-41655.s11">
        <title>References</title>
        <ref id="article-41655.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burns</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kula</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ashworth</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ornelas</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis.</article-title>
            <source>Adv Ther</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>37</volume>
            <issue>7</issue>
            <fpage>3265</fpage>
            <page-range>3265-3277</page-range>
            <pub-id pub-id-type="pmid">32447650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hesketh</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Kris</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Basch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bohlke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Barbour</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Clark-Snow</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Danso</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Dennis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dupuis</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Dusetzina</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Eng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Feyer</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Noonan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sparacio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lyman</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Antiemetics: ASCO Guideline Update.</article-title>
            <source>J Clin Oncol</source>
            <year>2020</year>
            <month>Aug</month>
            <day>20</day>
            <volume>38</volume>
            <issue>24</issue>
            <fpage>2782</fpage>
            <page-range>2782-2797</page-range>
            <pub-id pub-id-type="pmid">32658626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weibel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>R&#x000fc;cker</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Eberhart</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Pace</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Hartl</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>OL</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Riemer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Raj</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Backhaus</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Helf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schlesinger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kienbaum</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kranke</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2020</year>
            <month>Oct</month>
            <day>19</day>
            <volume>10</volume>
            <issue>10</issue>
            <fpage>CD012859</fpage>
            <pub-id pub-id-type="pmid">33075160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cove&#x000f1;as</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?</article-title>
            <source>Cancers (Basel)</source>
            <year>2020</year>
            <month>Sep</month>
            <day>20</day>
            <volume>12</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">32962202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Serafin</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Bottega</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>da Rosa</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Foletto</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Coelho</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>da Mota</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>H&#x000f6;rner</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Drug Repositioning in Oncology.</article-title>
            <source>Am J Ther</source>
            <string-date>2021 Jan-Feb 01</string-date>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>e111</fpage>
            <page-range>e111-e117</page-range>
            <pub-id pub-id-type="pmid">31033488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robinson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cove&#x000f1;as</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?</article-title>
            <source>Curr Med Chem</source>
            <year>2023</year>
            <volume>30</volume>
            <issue>16</issue>
            <fpage>1798</fpage>
            <page-range>1798-1812</page-range>
            <pub-id pub-id-type="pmid">35959620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuo</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Markova</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2022</year>
            <volume>9</volume>
            <fpage>898790</fpage>
            <pub-id pub-id-type="pmid">35770005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>He</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alhariri</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sweren</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kwatra</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Kwatra</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Aprepitant for the Treatment of Chronic Refractory Pruritus.</article-title>
            <source>Biomed Res Int</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>4790810</fpage>
            <pub-id pub-id-type="pmid">29057261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vincenzi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Guida</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Imperatori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schiavon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Venditti</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Frezza</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Berti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tonini</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.</article-title>
            <source>Lancet Oncol</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>10</issue>
            <fpage>1020</fpage>
            <page-range>1020-4</page-range>
            <pub-id pub-id-type="pmid">22995650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tattersall</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Rycroft</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pearce</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Merchant</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>MacLeod</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ladduwahetty</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Keown</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Swain</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cascieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ber</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Metzger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>MacIntyre</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Hargreaves</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets.</article-title>
            <source>Neuropharmacology</source>
            <year>1996</year>
            <volume>35</volume>
            <issue>8</issue>
            <fpage>1121</fpage>
            <page-range>1121-9</page-range>
            <pub-id pub-id-type="pmid">9121615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Maio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bria</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Banna</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Puglisi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Garassino</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Lorusso</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Perrone</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors.</article-title>
            <source>Anticancer Drugs</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-111</page-range>
            <pub-id pub-id-type="pmid">23165435</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Frimurer</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>W&#x000fc;thrich</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography.</article-title>
            <source>Nat Commun</source>
            <year>2019</year>
            <month>Feb</month>
            <day>07</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>638</fpage>
            <pub-id pub-id-type="pmid">30733446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hornby</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Central neurocircuitry associated with emesis.</article-title>
            <source>Am J Med</source>
            <year>2001</year>
            <month>Dec</month>
            <day>03</day>
            <volume>111 Suppl 8A</volume>
            <fpage>106S</fpage>
            <page-range>106S-112S</page-range>
            <pub-id pub-id-type="pmid">11749934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>The area postrema and vomiting.</article-title>
            <source>Front Neuroendocrinol</source>
            <year>1994</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>301</fpage>
            <page-range>301-20</page-range>
            <pub-id pub-id-type="pmid">7895890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Becker</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Nausea, vomiting, and hiccups: a review of mechanisms and treatment.</article-title>
            <source>Anesth Prog</source>
            <year>2010</year>
            <season>Winter</season>
            <volume>57</volume>
            <issue>4</issue>
            <fpage>150</fpage>
            <page-range>150-6; quiz 157</page-range>
            <pub-id pub-id-type="pmid">21174569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poli-Bigelli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rodrigues-Pereira</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carides</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Julie Ma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Eldridge</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hipple</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Horgan</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Lawson</surname>
                <given-names>F</given-names>
              </name>
              <collab>Aprepitant Protocol 054 Study Group</collab>
            </person-group>
            <article-title>Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.</article-title>
            <source>Cancer</source>
            <year>2003</year>
            <month>Jun</month>
            <day>15</day>
            <volume>97</volume>
            <issue>12</issue>
            <fpage>3090</fpage>
            <page-range>3090-8</page-range>
            <pub-id pub-id-type="pmid">12784346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nazl&#x00131;</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mesut</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>&#x000d6;zsoy</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>In Vitro Evaluation of a Solid Supersaturated Self Nanoemulsifying Drug Delivery System (Super-SNEDDS) of Aprepitant for Enhanced Solubility.</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2021</year>
            <month>Oct</month>
            <day>27</day>
            <volume>14</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">34832871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aapro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carides</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rapoport</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Schmoll</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Warr</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.</article-title>
            <source>Oncologist</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>450</fpage>
            <page-range>450-8</page-range>
            <pub-id pub-id-type="pmid">25795636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bubalo</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Cherala</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>McCune</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Munar</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Tse</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maziarz</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>586</fpage>
            <page-range>586-94</page-range>
            <pub-id pub-id-type="pmid">21415280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chawla</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Grunberg</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gralla</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Hesketh</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Rittenberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Elmer</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carides</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Horgan</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.</article-title>
            <source>Cancer</source>
            <year>2003</year>
            <month>May</month>
            <day>01</day>
            <volume>97</volume>
            <issue>9</issue>
            <fpage>2290</fpage>
            <page-range>2290-300</page-range>
            <pub-id pub-id-type="pmid">12712486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gan</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Diemunsch</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Habib</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Kovac</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kranke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Watcha</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Angus</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Apfel</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Bergese</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Candiotti</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Hooper</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Lagoo-Deenadayalan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Myles</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nezat</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Philip</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Tram&#x000e8;r</surname>
                <given-names>MR</given-names>
              </name>
              <collab>Society for Ambulatory Anesthesia</collab>
            </person-group>
            <article-title>Consensus guidelines for the management of postoperative nausea and vomiting.</article-title>
            <source>Anesth Analg</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>118</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <page-range>85-113</page-range>
            <pub-id pub-id-type="pmid">24356162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Apfel</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Malhotra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>The role of neurokinin-1 receptor antagonists for the management of postoperative nausea and vomiting.</article-title>
            <source>Curr Opin Anaesthesiol</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>427</fpage>
            <page-range>427-32</page-range>
            <pub-id pub-id-type="pmid">18660647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zagouri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dedes</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Papatheodoridi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liontos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dimopoulos</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Supportive medication in cancer during pregnancy.</article-title>
            <source>BMC Pregnancy Childbirth</source>
            <year>2020</year>
            <month>Dec</month>
            <day>01</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>747</fpage>
            <pub-id pub-id-type="pmid">33261562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alpuim Costa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nobre</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>de Almeida</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Gon&#x000e7;alves</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Braga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pais</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Cancer During Pregnancy: How to Handle the Bioethical Dilemmas?-A Scoping Review With Paradigmatic Cases-Based Analysis.</article-title>
            <source>Front Oncol</source>
            <year>2020</year>
            <volume>10</volume>
            <fpage>598508</fpage>
            <pub-id pub-id-type="pmid">33425755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kang</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Loftus</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>DiCristina</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zwaan</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>65</volume>
            <issue>10</issue>
            <fpage>e27273</fpage>
            <pub-id pub-id-type="pmid">29893452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salman</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>DiCristina</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chain</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Afzal</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and pharmacodynamics of aprepitant for the prevention of postoperative nausea and vomiting in pediatric subjects.</article-title>
            <source>J Pediatr Surg</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>54</volume>
            <issue>7</issue>
            <fpage>1384</fpage>
            <page-range>1384-1390</page-range>
            <pub-id pub-id-type="pmid">30381138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Borle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rewari</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Makkar</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Trikha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Goudra</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis.</article-title>
            <source>Postgrad Med J</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>92</volume>
            <issue>1084</issue>
            <fpage>87</fpage>
            <page-range>87-98</page-range>
            <pub-id pub-id-type="pmid">26627976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>dos Santos</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Brunetto</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Sasse</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>da Silveira Nogueira Lima</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2012</year>
            <month>Sep</month>
            <day>05</day>
            <volume>104</volume>
            <issue>17</issue>
            <fpage>1280</fpage>
            <page-range>1280-92</page-range>
            <pub-id pub-id-type="pmid">22911671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bailard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rebello</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>602</fpage>
            <page-range>602-603</page-range>
            <pub-id pub-id-type="pmid">29266364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leeder</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Piquette-Miller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dupuis</surname>
                <given-names>LL</given-names>
              </name>
            </person-group>
            <article-title>Aprepitant and fosaprepitant drug interactions: a systematic review.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>83</volume>
            <issue>10</issue>
            <fpage>2148</fpage>
            <page-range>2148-2162</page-range>
            <pub-id pub-id-type="pmid">28470980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aapro</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Walko</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Aprepitant: drug-drug interactions in perspective.</article-title>
            <source>Ann Oncol</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>21</volume>
            <issue>12</issue>
            <fpage>2316</fpage>
            <page-range>2316-2323</page-range>
            <pub-id pub-id-type="pmid">20488873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schoffelen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lankheet</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>van Herpen</surname>
                <given-names>CML</given-names>
              </name>
              <name>
                <surname>van der Hoeven</surname>
                <given-names>JJM</given-names>
              </name>
              <name>
                <surname>Desar</surname>
                <given-names>IME</given-names>
              </name>
              <name>
                <surname>Kramers</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Drug-drug interactions with aprepitant in antiemetic prophylaxis for chemotherapy.</article-title>
            <source>Neth J Med</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>76</volume>
            <issue>3</issue>
            <fpage>109</fpage>
            <page-range>109-114</page-range>
            <pub-id pub-id-type="pmid">29667586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langford</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chrisp</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting.</article-title>
            <source>Core Evid</source>
            <year>2010</year>
            <month>Oct</month>
            <day>21</day>
            <volume>5</volume>
            <fpage>77</fpage>
            <page-range>77-90</page-range>
            <pub-id pub-id-type="pmid">21042544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmitt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Goldschmidt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Neben</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Freiberger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>H&#x000fc;sing</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gronkowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thalheimer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pelzl</surname>
                <given-names>le H</given-names>
              </name>
              <name>
                <surname>Mikus</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Burhenne</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Egerer</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial.</article-title>
            <source>J Clin Oncol</source>
            <year>2014</year>
            <month>Oct</month>
            <day>20</day>
            <volume>32</volume>
            <issue>30</issue>
            <fpage>3413</fpage>
            <page-range>3413-20</page-range>
            <pub-id pub-id-type="pmid">25225424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yeo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mo</surname>
                <given-names>FKF</given-names>
              </name>
              <name>
                <surname>Yip</surname>
                <given-names>CCH</given-names>
              </name>
              <name>
                <surname>Yeo</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>TKH</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>VTC</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Pang</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kwok</surname>
                <given-names>CCH</given-names>
              </name>
              <name>
                <surname>Suen</surname>
                <given-names>JJS</given-names>
              </name>
              <name>
                <surname>Molassiotis</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Quality of Life Associated with Nausea and Vomiting from Anthracycline-Based Chemotherapy: A Pooled Data Analysis from Three Prospective Trials.</article-title>
            <source>Oncologist</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>26</volume>
            <issue>12</issue>
            <fpage>e2288</fpage>
            <page-range>e2288-e2296</page-range>
            <pub-id pub-id-type="pmid">34516038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aksu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dola&#x0015f;&#x00131;k</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ensaro&#x0011f;lu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sener</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Ayd&#x00131;n</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Temiz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cano&#x0011f;lu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Uygun</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of the efficacy of aprepitant on the prevention of chemotherapy-induced nausea and vomiting and quality of life with functional living index emesis.</article-title>
            <source>Balkan Med J</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>64</fpage>
            <page-range>64-7</page-range>
            <pub-id pub-id-type="pmid">25207071</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsuji</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Suetsugu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Muraoka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kanaya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Egashira</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ieiri</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Detection of overdose and underdose prescriptions-An unsupervised machine learning approach.</article-title>
            <source>PLoS One</source>
            <year>2021</year>
            <volume>16</volume>
            <issue>11</issue>
            <fpage>e0260315</fpage>
            <pub-id pub-id-type="pmid">34797894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r38">
          <label>38</label>
          <element-citation publication-type="book">
            <chapter-title>Aprepitant</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>7</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">31644204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kataria</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Kendre</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Ifosfamide-induced Encephalopathy Precipitated by Aprepitant: A Rarely Manifested Side Effect of Drug Interaction.</article-title>
            <source>J Pharmacol Pharmacother</source>
            <year>2017</year>
            <season>Jan-Mar</season>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-40</page-range>
            <pub-id pub-id-type="pmid">28405136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Downie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bayliss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stephenson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bluebond-Langner</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Daily Administration of Aprepitant for the Management of Intractable Nausea and Vomiting in Children With Life-Limiting Conditions: A Case Series.</article-title>
            <source>J Pain Symptom Manage</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>e225</fpage>
            <page-range>e225-e231</page-range>
            <pub-id pub-id-type="pmid">33587995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gummin</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Mowry</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Beuhler</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Spyker</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Bronstein</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Rivers</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>NPT</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>59</volume>
            <issue>12</issue>
            <fpage>1282</fpage>
            <page-range>1282-1501</page-range>
            <pub-id pub-id-type="pmid">34890263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Elkassabany</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Krug</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Fleisher</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Does the routine prophylactic use of antiemetics affect the incidence of postdischarge nausea and vomiting following ambulatory surgery?: A systematic review of randomized controlled trials.</article-title>
            <source>Anesthesiology</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>99</volume>
            <issue>2</issue>
            <fpage>488</fpage>
            <page-range>488-95</page-range>
            <pub-id pub-id-type="pmid">12883424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Majem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de Las Pe&#x000f1;as</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Virizuela</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cabez&#x000f3;n-Guti&#x000e9;rrez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lopez-Castro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>M&#x000e9;ndez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mond&#x000e9;jar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>MDM</given-names>
              </name>
              <name>
                <surname>Escobar</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>SEOM clinical guideline emesis (2021).</article-title>
            <source>Clin Transl Oncol</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>712</fpage>
            <page-range>712-723</page-range>
            <pub-id pub-id-type="pmid">35347571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Macario</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Truong</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Which clinical anesthesia outcomes are both common and important to avoid? The perspective of a panel of expert anesthesiologists.</article-title>
            <source>Anesth Analg</source>
            <year>1999</year>
            <month>May</month>
            <volume>88</volume>
            <issue>5</issue>
            <fpage>1085</fpage>
            <page-range>1085-91</page-range>
            <pub-id pub-id-type="pmid">10320175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ballatori</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Roila</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy.</article-title>
            <source>Health Qual Life Outcomes</source>
            <year>2003</year>
            <month>Sep</month>
            <day>17</day>
            <volume>1</volume>
            <fpage>46</fpage>
            <pub-id pub-id-type="pmid">14521717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41655.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ritchie</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Ellison</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ranganathan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sizemore</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vallejo</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Aprepitant: A Novel Medicaton in the Prevention of Postoperative Nausea and Vomiting.</article-title>
            <source>W V Med J</source>
            <year>2016</year>
            <season>Nov-Dec</season>
            <volume>112</volume>
            <issue>6</issue>
            <fpage>20</fpage>
            <page-range>20-4</page-range>
            <pub-id pub-id-type="pmid">29368823</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
